지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 거트앤리버 발행위원회 Gut and Liver Gut and Liver 제10권 제5호 KCI등재 SCOPUS
- 발행연도
- 2016.1
- 수록면
- 808 - 817 (10page)
이용수
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
초록· 키워드
오류제보하기
Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
Mohd Hanafiah K / 2013 / Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence / Hepatology 57:1333~1342
Shin HR / 2006 / Epidemiology of hepatitis C virus in Korea / Intervirology 49:18~22
Maasoumy B / 2012 / Natural history of acute and chronic hepatitis C / Best Pract Res Clin Gastroenterol 26:401~412
Perz JF / 2006 / The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide / J Hepatol 45:529~538
Bruno S / 2007 / Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study / Hepatology 45:579~587
Shin HR / 2006 / Epidemiology of hepatitis C virus in Korea / Intervirology 49:18~22
Maasoumy B / 2012 / Natural history of acute and chronic hepatitis C / Best Pract Res Clin Gastroenterol 26:401~412
Perz JF / 2006 / The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide / J Hepatol 45:529~538
Bruno S / 2007 / Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study / Hepatology 45:579~587
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
2019 .01
-
Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study
Gut and Liver
2016 .01
-
Quality of Life of Chronic Hepatitis C Patients and Its Associated Factors
Osong Public Health and Research Persptectives
2017 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response
Gut and Liver
2016 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Highly Effective Peginterferon α-2a plus Ribavirin Combination Therapy for Chronic Hepatitis C in Hemophilia in Korea
Clinical and Molecular Hepatology
2015 .01
-
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
Gut and Liver
2017 .07
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Clinical and Molecular Hepatology
2020 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
-
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
Clinical and Molecular Hepatology
2018 .01
-
Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index
Gut and Liver
2016 .01
-
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Clinical and Molecular Hepatology
2024 .07
-
Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study
Gut and Liver
2020 .01
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
Gut and Liver
2016 .01
-
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Clinical and Molecular Hepatology
2015 .01
-
PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis
Gut and Liver
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
첫번째 댓글을 남겨주세요.